EUCTR2020-006118-19-DE进行中（未招募）1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
Hutchison MediPharma Limited0 个研究点目标入组 76 人开始时间: 2021年3月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Has histologically or cytologically documented, locally advanced, or metastatic low- to intermediate-grade (grades 1 to 2) NETs and has progressed on at least 1 prior line of therapy, but no more than 3 therapies:
- •a. Cohort A: NET of lung origin
- •b. Cohort B: NET of small bowel origin
- •c. Cohort C: NET of non-small bowel, non-pancreas, and non-lung origin
- •d. Cohort D (DDI substudy): NET of any origin
- •2. Has radiologic evidence of progressive tumour within 12 months of study enrolment
- •3. Is willing and able to provide informed consent
- •4. Is =18 years of age
- •5. Has measurable lesions according to RECIST Version 1.1
- •6. Has absolute neutrophil count of =1.5×109/L, platelet count of = 100×109/L, and hemoglobin of =9 g/dL
- •7. Has serum total bilirubin of <1.5 times the upper limit of normal (ULN)
- •8. Has proteinuria of <2+ by urinalysis, or 24-hour urine collection of = 1 g of protein, or urine protein: urine-creatinine ratio of =1.9
- •9. Has ALT, AST, or alkaline phosphatase (ALP) levels of =2.5 times the ULN
- •a. Patients with known liver metastases may have ALT, AST, and ALP of =3× the ULN
- •10. Has serum creatinine of <1.5 times ULN or creatinine clearance of = 60 mL/min as estimated by the Cockcroft-Gault formula
- •11. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1 [Section 15])
- •12. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception that results in a low failure rate (<1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug. Such methods include oral, progestogen-only, hormonal contraception (combined
- •estrogen/progestogen should be avoided) or highly effective non-oral hormonal contraception (eg, Depo-Provera and Implanon) associated with inhibition of ovulation together with a barrier method (eg, diaphragm, always containing a spermicide), intrauterine device, intrauterine hormone-releasing system, bilateral tubal ligation, vasectomized partner, or sexual abstinence in line with the preferred and usual lifestyle of the subject. Oral and non-oral hormonal
- •contraception should always be combined with an additional contraceptive method (ie, barrier method) because of a potential interaction with the study drug. The same criteria are applicable to male patients involved in this clinical study if they have a partner of childbearing potential, and male patients must always use a condom.
- •A female is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (ie, =12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of the ovaries and/or uterus).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 38
排除标准
- •1. Has an AE due to previous antitumor therapy that has not recovered to CTCAE grade =1, except alopecia and peripheral neurotoxicity with CTCAE grade =2 caused by platinum chemotherapy
- •2. Major surgery within previous 4 weeks or radiation therapy within 2 weeks prior to the start of treatment (prior palliative radiotherapy for metastatic lesions is permitted if there is at least 1 measurable lesion that has not been irradiated)
- •3. Prior VEGF/VEGFR-targeted therapy
- •4. Has uncontrollable hypertension, defined as systolic blood pressure of =140 mmHg and/or diastolic blood pressure of =90 mmHg, despite antihypertensive medication
- •5. Prothrombin time (PT)/International normalized ratio (INR) of >1.5 or activated partial thromboplastin time (aPTT) of >1.5×ULN (for patients on Coumadin or Coumadin-like products, please refer to Section 7.3.3)
- •6. Has gastrointestinal disease or condition within 6 months prior to first dose that investigators suspect may affect drug absorption, including, but not limited to, active gastric and duodenal ulcers, ulcerative colitis and other digestive disease, gastrointestinal tumor with active bleeding, or other gastrointestinal conditions that could, in the investigators' judgment, result in bleeding or perforation
- •7. Has a history or presence of a serious hemorrhage (>30 mL within 3 months) or hemoptysis (>5 mL of blood within 4 weeks) within 6 months of first dose of study drug
- •8. Has clinically significant cardiovascular disease, including, but not limited to, acute myocardial infarction within 6 months prior to enrollment, evere/unstable angina pectoris or coronary artery bypass grafting, congestive heart failure of =2 according to the New York Heart Association classification, ventricular arrhythmia that needs drug treatment, and left ventricular ejection fraction (LVEF) of <50%
- •9. Has a mean corrected QT interval by Fridericia (QTcF) of =480 ms
- •10. Has brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer (patients requiring steroids within 4 weeks prior to start of study treatment will be excluded)
- •11. Has a high risk of bleeding at screening due to tumor invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators
- •12. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischemic attack) within 6 months prior to the first dose of study drug
- •13. Use of strong or moderate inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of surufatinib (see Appendix 3 [Section 15] for examples)
- •14. For Cohort D, use of medications that are known substrates, inhibitors, or inducers of CYP3A or substrates of P-gp or BCRP within 3 weeks before the first dose of the drug cocktail (see Appendix 3 [Section 15] for examples)
- •15. Prior history of other cancers, except those treated with curative intent for in situ non-melanoma skin cancer, breast or cervical cancer, or those treated with curative intent and no evidence of disease in the last 5 years prior to enrollment in the study
- •16. Has a clinically meaningful ongoing infection (eg, requiring intravenous treatment with anti-infective therapy)
- •a. See Appendix 8 (Section 15)for procedures specific to subjects with suspected or confirmed coronavirus disease 2019 (COVID-19)
研究者
相似试验
进行中（未招募）
1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europeeuroendocrine TumoursMedDRA version: 21.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-006118-19-ITHutchison MediPharma Limited76
招募中
1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in EuropeEUCTR2020-006118-19-FRHutchison MediPharma Limited76
进行中（未招募）
1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in EuropeEUCTR2020-006118-19-ESHutchison MediPharma Limited76
进行中（未招募）
1 期
Surufatinib in Combination With Tislelizumab in Advanced Solid TumorsEUCTR2020-004163-12-ESHutchison MediPharma Limited107
终止
2 期
Open-Label Surufatinib in European Patients With NETNeuroendocrine TumoursNeuroendocrine Tumour of the LungSmall Intestinal NETNCT04579679Hutchmed78